Episode 3: Cracking the Code of Small Renal Masses: Sestamibi, MRI, & Targeted RCC Detection

Episode 2: Rethinking Prostate Biopsy: Safer, Smarter, and Beyond the Rectum

Episode 1: Are We Ready for Biology Driven Bladder Cancer Care

Learn About 'Beyond the Biopsy' With Dr Nitin Yerram

Patient Centered Care and Cutting Edge Science at SUO 2025

Upper Tract Urothelial Carcinoma Key Challenges and Expert Solutions

Patient Selection and Surgical Considerations for Female Organ Sparing Cystectomy

Digital Pathology and AI in Bladder Cancer

Why Urologists Must Become Advocates Policy, Payment, and the Future of Care

Emerging Therapies: Bispecifics, PARP Inhibitors, and Novel Radioisotopes

Overcoming Treatment Challenges in Heavily Pretreated Prostate Cancer

Choosing Between Abiraterone and Novel ARPIs: Practical Insights

PSMA-PET, Genetic Testing, and Imaging Challenges in Early Prostate Cancer

Case-Based Approaches to Aggressive Disease, Biochemical Recurrence

Bridging Local and Metastatic Disease: Salvage Approaches and the Role of Molecular Testing

Navigating CRPC: PARP Inhibitors, Radioligands, and Sequencing Strategies

Optimizing First-Line Therapy in Metastatic Disease: From ARANOTE to Dose Adjustments in Practice

Looking Ahead: Innovative Treatments and Precision Approaches in Prostate Cancer

Focal Therapy, Functional Imaging, and the Role of AI in Modern Prostate Cancer Care

Navigating Unfavorable IR Disease: Imaging, Staging, and Local Therapy Decisions

Chemo Free or Chemo First Navigating Lu-PSMA-617, Radium, and Treatment Sequencing

The Road Ahead: Molecular Profiling, Novel Agents, and Quality-of-Life Considerations

Access, Tolerability, and Trial Limitations: Practical Decision-Making in CRPC

Evolving Standards: Triplet Therapy and the Role of Bone-Directed Agents

Therapy Buckets in Practice: Personalizing Treatment Pathways in Advanced Prostate Cancer

Identifying High-Risk Patients: Predictors of Progression to CRPC

From Tumor Boards to Trials: Evolving Approaches in Oligometastatic Prostate Cancer

Upfront Testing and Monitoring: Practical Approaches in Metastatic Prostate Cancer

Next Steps for EV/Pembro: Toxicity Management, ctDNA, and Emerging Trials

When to Scale Back: Insights from an Ongoing EV/Pembro De-Escalation Pilot Study

De-Escalation Strategies with EV/Pembro: Clinical Rationale and Evidence

Looking Ahead: Gaps, Hurdles, and Transition in Current Phase 2 RLT Trial Landscape

Key Trends in Ongoing Phase 2 RLT Trials

Expanding the Reach: TAR-200 in Papillary Disease and Beyond

Combination Therapy in SunRISe-1: Lessons from Cetrelimab and TAR-200

Primary vs Nodal Response: What Discordance Means for Surgical Planning

Robotic vs Open Cytoreductive Cystectomy: Lessons from Early Experience

Stopping Systemic Therapy: When Surgery Enables a Treatment Holiday

Cytoreductive Cystectomy After EV-302: How We Got Here

HRD Signatures, PARP, and Radiation: Where Science Meets Practice

Emerging Frontiers: T-Cell Engagers, Radioligands, and BCR

Balancing ARPI Use, PSA Response, and Genomics in Treatment Planning

Radium-223 vs Lu-PSMA-617: Evolving Roles in Bone-Predominant mCRPC

Choosing the Right ARPI: Clinical and Practical Considerations

High-Volume Disease in the PSMA-PET Era: Trials, Imaging, and Real-World Decisions

Upfront Treatment Strategies for De Novo Metastatic Prostate Cancer

Advancing Therapies for Chromophobe RCC: KIT as a Gateway for Targeted Drug Delivery

The Future of NMIBC Treatment: Going Beyond the Standard of Care Through Shared Decision Making

ENVISION Trial Update: Integrating a New Treatment into NMIBC Standard of Care

Redefining Treatment in Intermediate-Risk NMIBC: Navigating an Evolving Landscape

Perioperative Advances and ctDNA: The Next Frontier in Metastatic Bladder Cancer

Platinum Rechallenge, Immunotherapy, and Evidence Gaps in Metastatic Bladder Cancer

Breaking the Platinum Ceiling: Key Insights in Advanced Bladder Cancer

Efficacy and Durability of Response in SunRISe-1

TAR-200 in Focus: Early Experience and Patient Impact

How Trials and Targeted Therapies Are Reshaping Prostate Cancer Care

Abiraterone, Enzalutamide, Darolutamide, and Apalutamide: How Oncologists Decide

Defining Low vs High Volume: STAMPEDE and PEACE-1 Guiding Practice

Evolving Technologies vs Practical Biomarkers in Prostate Cancer Management

Early-Stage Prostate Cancer Workup: Imaging, Genomics, and Patient Health